Michael Kimerling, Senior Program Officer, Tuberculosis Global Health Program, BMGF, suggested that SLDAII fills an important niche in the current environment in helping to ensure coordination and actionoriented progress, but noted that it is open to revision; evaluation is currently underway with the view to ensuring that the right partners are being involved and properly engaged. He said that in moving forward strategically, a shift in focus is needed from identifying barriers to creating innovative solutions and from writing documents to writing business plans. Integrating the private sector will require learning its language and analyzing its needs, which will aid in adapting to a changing market. All efforts should be focused on working urgently and systematically toward a common and clearly established set of principles: ensuring uninterrupted and universal access to the QA drugs at affordable prices.
MDR TB Innovation Summit
Tracy Sims, Vice President, Eli Lilly & Co. Foundation, described ideas that were generated in an MDR TB Innovation Summit that was convened in May 2012.b The Innovation Summit tackled the following clearly defined problem statement:
What innovative approaches/products can be implemented (either directly or indirectly) that would overcome the supply chain barriers that today prevent IQA SLDs from reaching the entire global population of MDR TB patients?
The Summit included participants from both within and outside the sphere of MDR TB expertise who were tasked with dissecting the problem, analyzing it, and producing actionable outcomes. The underlying strategic concepts driving the Summit were the need to take action, develop new approaches, involve new people, engage in partnership, and take well-informed risks.
The initial step in the process employed at the 2-day Summit was to clearly identify the problem and segregate the problem space into five pieces:
1. demand for care;
2. purchasing and procurement;
3. production, QA, and QC;
4. logistics; and
5. delivery of care.
Barriers to the delivery of medication from both the supply and demand sides were identified, and the participants were divided into teams to address each of the identified barriers separately. The teams developed